WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
At least 1 dead in Florida as storms continue to pummel the South in a week of severe weatherZurich presents counterrevolutionary staging of Wagner's Ring Cycle under Noseda and HomokiRussia: Putin reappoints Mikhail Mishustin as prime ministerDR MICHAEL MOSLEY: Why eating at a snail's pace works like OzempicAustralian judge extends ban on X sharing video of Sydney bishop's stabbingSyria's KurdishSweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024PGA CHAMPIONSHIP '24: Facts and figures for the PGA at ValhallaGunmen abduct 9 students in Nigeria's north in the latest attack targeting schoolsPolice arrest brother and lawyer of Peru's president over alleged influence peddling
2.7257s , 5260.5078125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Channel news portal